| Literature DB >> 29802937 |
Sanchari Bhattacharya1, Laboni Mondal1, Biswajit Mukherjee2, Lopamudra Dutta1, Iman Ehsan1, Mita C Debnath3, Raghuvir H Gaonkar3, Murari M Pal1, Subrata Majumdar4.
Abstract
Hepatocellular carcinoma (HCC) is one of the major causes of cancer related death globally. Apigenin, a dietary flavonoid, possesses anti-tumor activity against HCC cells in-vitro. Development, physicochemical characterization of apigenin loaded nanoparticles (ApNp), biodistribution pattern and pharmacokinetic parameters of apigenin upon intravenous administration of ApNp, and effect of ApNp treatment in rats with HCC were investigated. Apigenin loaded nanoparticles had a sustained drug release pattern and successfully reached the hepatic cancer cells in-vitro as well as in liver of carcinogenic animals. ApNp predominantly delayed the progress of HCC in chemical induced hepatocarcinogenesis in rats. Quantification of apigenin by liquid chromatography-mass spectroscopy (LC-MS/MS) showed that apigenin availability significantly increased in blood and liver upon ApNp treatment. Apigenin loaded nanoparticle delivery substantially controlled the severity of hepatocellular carcinoma and could be a future hope for lingering the survival in hepatic cancer patients.Entities:
Keywords: Apigenin nanoparticles; Gamma scintigraphy; Hepatocellular carcinoma; Histopathology; LC-MS/MS; Pharmacokinetics
Mesh：
Substances：
Year: 2018 PMID： 29802937 DOI： 10.1016/j.nano.2018.05.011
Source DB: PubMed Journal: Nanomedicine ISSN： 1549-9634 Impact factor: 5.307